Agoracom Blog

VIDEO – Isareli-Based Innocan $ Distribution and Manufacturing Agreements, In Both Europe and USA, Point To Commercialization Of Clinically Proven #CBD Products In 2021 $ $APHA $ $

Posted by AGORACOM-JC at 5:16 PM on Thursday, November 19th, 2020

2020 has been a disappointing one for the once euphoric cannabis industry thanks to the fallout of over-hyped and over-financed companies that failed to deliver on a fraction of their promises.  

The year 2000 saw the exact same thing happen to “dot-com” companies that failed in even more spectacular fashion.  Many investors swore off internet stocks forever. 

The smart ones waited to see which companies were real … and the rest was history as we saw the birth and growth of internet companies that delivered real value, products and customers.    

The same is about to happen in the Cannabis space.  With the market estimated to hit $70 Billion over the next few years, there is very little doubt that winners will be created out of companies delivering real businesses.

Enter Innocan Pharma Corporation (INNO:CSE) (IP4: FSE) and it’s incredible team of accomplished scientists led by CEO Iris Bincovich.  

As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products, the latter of which have already announced distribution and manufacturing agreements throughout Europe and the United States.

If you believe in the future of the cannabis and companies delivering real, value-add CBD products, then watch this interview with Innocan CEO, Iris Bincovich.

Tags: , , , , , , , , , ,

Comments are closed.